| Scientific program – 04.12.2026

Friday, December 4

from 08.00	Door opening Networking Area	Networking Area
08.30–09.45	**General Assembly SGN/SSN**	**Room Aare**
09.45–10.00	**SGN Publication Award 2026** Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial **Dr. Manuel Anderegg, Bern**	**Room Aare**
10.00–10.15	Short break	Networking Area
10.15–11.00	Transplant Challenges in Genetic Diseases **Prof. Dr. med. Wesley Hayes, Zürich** **Dr. med. Alexander Ritter, St. Gallen** Chair: Dr. med. Sybille Tschumi, Bern	Room Aare **Parallel Symposium by Alnylam Switzerland GmbH**
10.15–11.00	Proteinuria and Beyond: Redefining Kidney Protection in IgAN & LN Proteinuria Toxicity: What's New? **Prof. Dr. Sophie de Seigneux, Genève** Beyond Proteinuria: Targeting Disease Remission and Kidney Protection **PD Dr. Harald Seeger, Baden** Chair: Prof. Uyen Huynh-Do, Bern	Room Szenario **Parallel Symposium by Otsuka Pharmaceutical (Switzerland) GmbH**
11.00–11.30	Coffee break	Networking Area
11.30–12.15	**State of the Art Lecture 4:** Primary Aldosteronism: State-of-the-Art- From Pathophysiology to Clinical Practice Primary Aldosteronism: From Adrenal Biology to Pathophysiology **Dr. Tracy Ann Williams, München (GER)** Primary Aldosteronism: From New Guidelines to Clinical Practice **Prof. Paolo Mulatero, Torino (IT)**	Room Aare

Friday, December 4

11.30–12.15	Advancing Understanding of C3G and Primary IC-MPGN: Transplantation and Real-World Perspectives Transplantation in C3G and Primary IC-MPGN: Clinical Considerations **Prof. Patricia Hirt-Minkowski, Basel** Pegcetacoplan: 76-Week Follow-Up and Real-World Experience **PD Dr. Harald Seeger, Baden** Chair: Prof. Uyen Huynh-Do, Bern	Room Szenario **Parallel Symposium by Swedish Orphan Biovitrum AG**
12.15–13.00	**YSN Picture Challenge**	Room Aare
12.15–13.00	Changing the Tune in IgA Nephropathy: Clinical Advances and Swiss Real-World Experience Setting the Scene: Key Concepts from the New Guidelines **Prof. Uyen Huynh-Do, Bern** Optimizing IgAN Care: The Role of Endothelin Pathway Inhibition in Improving Outcomes **PD. Dr. Min Jeong Kim, Aarau** Targeting the Immune Drivers of IgAN: Emerging Therapies and Implementation in Clinical Practice **Dr. Stephanie Damm, Zurich** Chair: Prof. Uyen Huynh-Do, Bern	Room Szenario **Parallel Symposium by Novartis Pharma Schweiz AG**
13.00–14.00	Lunch break	Networking Area
14.00–14.45	Resistant Hypertension and CKD: Clinical Evidence with Aprocitentan The unmet need in resistant hypertension and CKD **Prof. Michel Burnier, Lausanne** The Endothelin System: From Physiology to Clinical Relevance **Dr. Alessandro Maresta, Allschwil** Aprocitentan in Resistant Hypertension and CKD: Clinical Evidence and Relevance for Clinical Practice **Prof. Michel Burnier, Lausanne**	Room Aare **Idorsia Pharmaceuticals Germany GmbH**

Friday, December 4

14.00–14.45	**State of the Art Lecture 5:** Thrombotic thrombocytopenic purpura (TTP) Congenital TTP : how to recognize, how to treat **Prof. Anne Sophie von Krogh, Trondheim (NOR)** Treatment of immune-mediated TTP in 2026 **Prof. Dr. med. Johanna Anna Kremer Hovinga, Bern**	Room Szenario
14.45–15.30	**Electrolyte Masterclass** **YSN educational program** Prof. Thomas Fehr, Chur PD Dr. med. Matthias Diebold, Basel	Room Aare
14.45–15.30	Recap CKM **Dr. Barnaby Hole, Bristol (UK)** **Dr. Sara Davison, Edmonton (CAN)** Panel Discussion - CKM: building a Swiss roadmap **Marta Aramini, Lugano** **Dr. Valerie Luyckx, Zürich** **Prof. Olivier Bonny, Fribourg** **Dr. Stefan Pelz, Aarau** **Prof. Pietro Cippà, Basel** **Dr. Andrea Viecelli, Zürich**	Room Szenario
15.30	**Farewell address**	Room Szenario